

Should Postprandial Glucose Be Measured and Treated to a Particular Target? Yes.

JAIME DAVIDSON, MD

In August 2001, the American College of Endocrinology (ACE) published its recommendations for glycemic targets in the management of diabetes. Included in those recommendations was a target for 2-h postprandial glucose (PPG) of <140 mg/dl; current American Diabetes Association (ADA) guidelines do not include a PPG target, nor have they for several years. The European Association for the Study of Diabetes (EASD/IDF-Europe) have a postprandial target of <7.5 mmol/l (135 mg/dl) as well.

Ever since ACE presented its recommendations to the health care community, there has been considerable debate about the appropriateness of recommending a PPG target to the health care community and lay public. Should PPG be monitored and treated? If so, what should the goal be?

The purpose of this report is to answer some central questions regarding the evidence and rationale that support the use of a 2-h postprandial target of <140 mg/dl. The goal is to provide health care providers and other interested parties with the information they need to make informed decisions about patient care.

It is important to note that although this debate has been broadened to include issues regarding the frequency of testing, no organization has proposed any form of recommendation for "routine" PPG testing.

How well are we doing with diabetes care in America today?

Epidemiological studies have shown very significant correlations between glycemic status and both microvascular and macrovascular complications (1). Furthermore, tight glycemic control in interventional studies unequivocally delayed, and possibly prevented, the development and progression of the microvascular complications (2–4). Additionally, there is no glycemic threshold for risk reduction, even into the normal range; the lower the A1C, the less risk of complications (1).

Despite new advances in therapies and glucose monitoring technology, combined with our growing understanding of diabetes and its complications, we have been unsuccessful in achieving tight glycemic control in our patients using the ADA guidelines. National Health and Nutrition Examination Survey III data revealed that among American adults (>20 years of age) with diabetes, ~37% had A1C concentrations >8% and 14% had concentrations >10% (5). These findings align with the results from a recent, unpublished survey of 100 primary care providers, in which ~58% of respondents indicated they would not start pharmacological therapy until a patient's A1C reached $\geq 8.0\%$ (6).

Furthermore, analysis of data from nine large community studies of type 2 diabetes, covering Caucasians and high-

risk ethnic populations, shows mean 2-h PPG ranges from 235 to 349 mg/dl (7).

What is the relationship between PPG and overall glycemic control?

Postprandial hyperglycemia is one of the earliest detectable abnormalities expressed in diabetes (8) and may be a better predictor of progression to diabetes than measurements of fasting glucose. Furthermore, PPG is also a significant contributor to mean plasma glucose, which is the key predictor of glycemic control as measured by A1C (9–12).

Bonora et al. (10) showed that A1C levels are more closely related to preprandial rather than postprandial glucose levels, even though the majority of patients studied had extremely elevated glucose excursions with meals and extended periods of postprandial hyperglycemia.

Avignon et al. (11), however, found that post-lunch plasma glucose and extended post-lunch plasma glucose was more reliable in predicting poor glycemic control than pre-breakfast or pre-lunch plasma glucose.

Whether PPG or fasting plasma glucose is the stronger predictor of overall glycemic control is certainly debatable; the fact that PPG is a strong contributor to glycemic control is not.

What is a normal PPG value?

According to the ADA consensus panel on PPG, PPG levels in nondiabetic individuals rarely rise above 140 mg/dl and then return to normal preprandial levels within 2–3 h (13). Therefore, given that normal postprandial levels are usually well below 100 mg/dl, the ACE 2-h PPG target of <140 mg/dl is quite reasonable, even generous.

The fact that glucose levels are maintained very tightly in nondiabetic individuals reflects the importance of PPG levels. Additionally, the ADA already recognizes that impaired glucose tolerance, a 2-h PPG between 140 and 200 mg/dl, is abnormal (13).

From the UTSWMS, Endocrine and Diabetes Association of Texas, Dallas, Texas.

Address correspondence and reprint requests to Jaime Davidson, MD, UTSWMS, Endocrine and Diabetes Association of Texas, 7777 Forest Ln., Suite B-445, Dallas, TX 75230. E-mail: endodiab@medicalcitydallas.com.

Received and accepted for publication 1 April 2003.

This commentary was intended to be part of a Point/Counterpoint feature discussing the value of postprandial glucose measurements. (See the commentary by John Buse: Should postprandial glucose be routinely measured and treated to a particular target? No! *Diabetes Care* 26:1615–1618, 2003.)

Abbreviations: ACE, American College of Endocrinology; ADA, American Diabetes Association; PPG, postprandial glucose.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2003 by the American Diabetes Association.

Does targeting postprandial hyperglycemia improve overall glycemic control?

Feinglos et al. (14) showed that using insulin lispro to target postprandial hyperglycemia in patients with type 2 diabetes not only improved PPG control but also reduced both fasting glucose and A1C levels from 9.0 to 7.1%.

Furthermore, a study by Bastyr et al. (15) showed that therapies that focused on lowering PPG versus fasting glucose are better for lowering glycated hemoglobin levels.

Finally, De Veciana et al. (16) clearly demonstrated that targeting treatment to 1-h PPG levels rather than fasting glucose significantly reduces A1C in pregnant women and improves neonatal outcomes. These outcomes lead to fewer C-sections and decreased admission of neonates to the intensive care unit. Clearly, PPG control in pregnancy results in a substantial economic benefit.

Is PPG an independent contributor to diabetes outcomes?

A study by de Vegt et al. (17) found that the degree of risk conferred by the 2-h PPG concentration was nearly twice that conferred by A1C level.

Other recent studies (18,19) have demonstrated that even moderate postprandial hyperglycemia (148–199 mg/dl) is not only more predictive of atherosclerosis than fasting glucose, but also may have direct adverse effects on the endothelium.

Although numerous epidemiological studies (17–21) have shown elevated postprandial/postchallenge glucose to be independent and significant risk factors for macrovascular complications and increased mortality risk, it is not known if PPG is an independent contributor to diabetes outcomes.

Is managing PPG safe?

Although the percentage of severe hypoglycemia in the Diabetes Control and Complications Trial (1) was high in the intensive treatment group, the number of patients who actually experienced hypoglycemia was small.

The VA Cooperative Study (22) showed severe hypoglycemic reactions to be extremely rare among intensively treated patients, and not significantly different from those among conventionally treated patients.

The Kumamoto study (2) showed no

severe hypoglycemia >8 years in either the intensively or the conventionally treated group.

The U.K. Prospective Diabetes Study (3,23) did show severe hypoglycemia in intensively treated patients (0.1–2.3% per year). However, even patients treated with diet therapy alone also reported severe hypoglycemia. The reporting of severe hypoglycemia among patients treated nonpharmacologically (0.03% per year) raises some question about the actual incidence of true severe hypoglycemia.

Regardless of the differences in reported hypoglycemia in these studies (2,3,23), all of them have shown that the risk of severe hypoglycemia in type 2 diabetes is significantly less than in type 1 diabetes.

Is managing PPG even possible?

Today's new pharmacological therapies, blood glucose monitoring technologies, and innovative treatment strategies make it possible to safely and effectively manage PPG.

In addition to new rapid-acting and long-acting insulin analogs (24–27), there are also rapid-acting oral secretagogues, such as repaglinide and nateglinide, that have been shown to be safe and effective in controlling PPG excursions (28,29). Other drugs such as α -glucosidase inhibitors also work by lowering PPG levels (30). Many of the existing sensitizers also have a positive effect on postprandial hyperglycemia, in addition to lowering fasting glucose (31).

Furthermore, a recent study of non-insulin-treated patients with type 2 diabetes by Schwedes et al. (32) showed that meal-related self-monitoring of blood glucose not only improved overall glycemic control but also resulted in significant improvement of general well-being.

Why would we not set a goal for PPG?

How many clinicians did not strive to achieve near-normal glycemia in our type 1 diabetic patients before 1993 when results from the Diabetes Control and Complications Trial were announced? How many did not strive to achieve near-normal glycemia in our type 2 diabetic patients before announcement of the U.K. Prospective Diabetes Study's results in 1998?

We already know that elevated glucose in the fasting state is harmful and that

an elevated postprandial before diagnosis of diabetes increases the risk of cardiovascular complications. How, then, can we consider postprandial hyperglycemia to be of no significance once the diagnosis is made? It does not make sense to not monitor and manage PPG.

Managing diabetes is both an art and a science. It is an art in regard to the clinical judgment we use to make decisions about patient needs and therapies. The science provides the base knowledge in our research. Both clinical judgment and evidence-based knowledge are critical to our ability to effectively treat patients.

Science shows that postprandial hyperglycemia is a significant contributor to overall glycemic control and possibly an independent contributor to diabetes outcomes. Therefore, sound clinical judgment dictates that it should be managed. Furthermore, the ADA guidelines (13) clearly state PPG monitoring may be considered during pregnancy and when using medications that treat postprandial hyperglycemia. But as the saying goes, "You can't manage what you don't measure." Clearly a 2-h PPG target of <140 mg/dl is both reasonable and responsible.

References

1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 321:405–412, 2000
2. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329:977–986, 1993
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 28:103–117, 1995
4. The UKPDS Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 352:837–853, 1998
5. Narayan KMV, Gregg EW, Engelgau MM, Moore B, Thompson TJ, Williamson DF, Vinicor F: Translation research

- for chronic disease: the case of diabetes. *Diabetes Care* 23:1794–1798, 2000
6. IMS Health: *IMS Physician Survey*. Fairfield, CT, IMS Health, 2001
 7. Edelman SV, Henry RR: *Diagnosis and Management of Type II Diabetes*. 5th ed. Professional Communications, 2002
 8. Gerich JE: *Hormone Metab Res* 28:404–412, 1996
 9. American Diabetes Association: Postprandial blood glucose (Consensus Statement). *Diabetes Care* 24:775–778, 2001
 10. Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna R, Muggeo M: Plasma glucose levels throughout the day and HbA_{1c} interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. *Diabetes Care* 24:2023–2029, 2001
 11. Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. *Diabetes Care* 20:1822–1826, 1997
 12. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W: Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. *Diabetes Res Clin Pract* 46:23–27, 1999
 13. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 25 (Suppl. 1):S33–S49, 2002
 14. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD: Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. *Diabetes Care* 20:1539–1542, 1997
 15. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE, the IOEZ Study Group: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA_{1c}. *Diabetes Care* 23:1236–1241, 2000
 16. De Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT: Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. *N Engl J Med* 333:1239–1241, 1995
 17. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 42:926–931, 1999
 18. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurkschiev T: Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. *Atherosclerosis* 144:229–235, 1999
 19. Temelkova-Kurkschiev TS, Koehler C, Henkel D, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA_{1c} level. *Diabetes Care* 23:1830–1834, 2000
 20. DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. *Lancet* 354:617–621, 1999
 21. Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry (Honolulu Heart Program). *Diabetes* 36:689–692, 1987
 22. Abaira C, Henderson WG, Colwell JA, Nuttall FP, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK, VA CSDM Group: Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM). *Diabetes Care* 21:574–579, 1998
 23. UK Prospective Diabetes Study Group: U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. *Diabetes* 44:1249–1258, 1995
 24. Jacobon L, Sogaard B, Riis A: Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. *Eur J Clin Pharmacol* 56:399–403, 2000
 25. Roach P, Trautmann ME, Anderson JH, the Mix25 Study Group: Improved postprandial glycemia during treatment with an intermediate-acting insulin mixture, Mix25 (Abstract). *Diabetologia* 41 (Suppl.1):A244, 1998
 26. Roach P, Trautmann M, Anderson J, the LM Study Group: Lower incidence of nocturnal hypoglycemia during treatment with a novel protamine-based formulation of insulin lispro (Abstract). *Diabetes* 47 (Suppl.1):A92, 1998
 27. Riddle M: *American Diabetes Association Annual Meeting, 2002*. San Francisco, CA, June, 2002
 28. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG: A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. *Diabetes Care* 21:1897–1903, 1998
 29. Gribble FM, Manley SE, Levy JC: Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). *Diabetes Care* 24:1221–1225, 2001
 30. Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimmel D, Weiss S, Taylor T, Krol A, Magner J: Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. *Diabetes Care* 21:2056–2061, 1998
 31. Rosenstock J, Donovan D, Piper BA: Effect of metformin/glyburide tablets on postprandial insulin as first-line in type 2 diabetes. *Diabetes* 49 (Suppl. 1):A364, 2000
 32. Schwedes U, Siebolds M, Mertes G, the SMBG Study Group: Meal-related structured self-monitoring of blood glucose: effects on diabetes control in non-insulin-treated type 2 diabetic patients. *Diabetes Care* 25:1928–1932, 2002